SOFIVA Genomics, a leading brand in genetic testing, today announced a record-high revenue of NTD $47.692 million in May. With an accumulated annual revenue of NTD $212.564 million thus far, SOFIVA has marked a 5.39% YoY growth. Chia-Cheng Hung, General Manager of SOFIVA, expressed, "We've noticed that high-end testing products are gradually gaining public preference. We'll continue to target the high-end genetic testing market and expand our R&D investments into developing testing products that meet market demand."
SOFIVA’s Operations Soar as High-End Testing Becomes Mainstream
Exponential sales growth of SOFIVA NIPS v2.0 and v3.0 contributed to the record-high revenue in May. Compared to the average monthly sales of 2020, the NIPS v3.0 growth 40% and a roughly 30% growth of the NIPS v2.0 and v3.0 combined. Chia-Cheng Hung, General Manager of SOFIVA, emphasized, "Consumers' rising awareness of health-related testing and precision medicine has pushed high-end and comprehensive genetic testing services into the mainstream market. This trend is reflected by the outstanding sales performance of our non-invasive prenatal screening products, NIPS v2.0 and v3.0.
We are extremely optimistic about the future of the genetic testing market. Therefore, we plan to continue expanding our investment in the research and development of high-end testing services for reproductive medicine, prenatal women, newborns, cancer, and precision medicine, as well as develop genetic testing products that meet market demand."
SOFIVA Gains CAP Recognition; International Accreditation Bolsters Business Expansion
Public sentiment towards the international accreditation of precision medicine and genetic testing services and technologies has risen considerably in recent years. SOFIVA's Medical Laboratory was awarded CAP accreditation in the first half of this year, becoming the first genetic testing laboratory in Taiwan to gain triple accreditation (CAP, ISO/IEC 17025, and ISO9001). Dr. Yi-Ning Su, Chairman of SOFIVA, expressed, "Gaining CAP accreditation not only raises our testing quality to international standards, expands international visibility, and creates new collaboration opportunities with international pharma but also helps in establishing new partnerships, strengthening our competitiveness in foreign markets, and increasing our market share and penetration."